Home Notice Board [News Letter] Covid-19 Vaccine Development

[News Letter] Covid-19 Vaccine Development

[12/03/2021] Status of Development & Strategy for COVID-19 Vaccine Mar-13-2021
Writer Global Cooperation Dept.

※ 국문 요약내용 첨부 문서 참조 안내 (Please refer to the attached file for the korean summary)



[1] Neue Hoffnung: Corona-Impfstoff von Novavax hat Wirksamkeit von 96 Prozent

    (새로운 희망: 노바백스 코로나 백신 96% 효능)


Source : Business Insider

Link : https://www.businessinsider.de/wissenschaft/gesundheit/neue-hoffnung-corona-impfstoff-von-novavax-hat-wirksamkeit-von-96-prozent/



[2] COVID-19: Paracetamol & Co gegen Impfnebenwirkungen nicht zu früh einnehmen

    (코로나 19: 백신 부작용에 대해 파라세타몰(타이레놀)을 너무 일찍 복용하지 말아야)


Source : Ärtzeblatt

Link : https://www.aerzteblatt.de/nachrichten/121976/COVID-19-Paracetamol-Co-gegen-Impfnebenwirkungen-nicht-zu-frueh-einnehmen

 


[3] THROMBOSE ALS NEBENWIRKUNG BEI ASTRAZENECA - 11 FÄLLE AUS DEUTSCHLAND

    (아스트라제네카 부작용으로서 혈전증 - 독일에서 11)


Source : Mitteldeutscher Rundfunkt

 Link : https://www.mdr.de/wissen/corona-astrazeneca-impfungen-ema-ueberprueft-nebenwirkungen-100.html

 


[4] Neue Studie, „Impfpfad“ macht Hoffnung: Ende Juli könnte Deutschland mit dem Impfen durch sein

    (새로운 연구 "백신경로" 희망 제시: 독일은 7월말까지 백신접종 완료 가능)


Source : Focus

Link : https://www.focus.de/gesundheit/coronavirus/neue-studie-neue-studie-alle-impfwilligen-koennten-schon-bis-ende-juli-geimpft-sein_id_13076102.html

 


[5] Dritte Corona-Welle, Während jeder auf Briten-Mutante blickt, entschlüsseln Forscher viel aggressivere Variante

    (3차 코로나 유행, 영국 변이를 보고 있는 동안 연구원들은 훨씬 더 공격적인 변이를 분석중)


Source : Focus

Link : https://www.focus.de/gesundheit/news/dritte-corona-welle-waehrend-jeder-auf-briten-mutante-blickt-entschluesseln-forscher-viel-aggressivere-variante_id_13059987.html

File [Kor.version] 12032021.pdf
Prev [11/03/2021] Status of Development & Strategy for COVID-19 Vaccine
Next [15/03/2021] Status of Development & Strategy for COVID-19 Vaccine
Page Editor
Global Cooperation / Jae Sang Lee
TEL
+49-(0) 681-9382-376
E-mail